Biotech Startups

Virica develops small-molecule cell enhancers called Viral Sensitizers (VSE) that temporarily reduce host cell defenses to increase viral vector yields, quality, and scalability during production. Its products serve cell and gene therapy and vaccine manufacturers, aiming to lower manufacturing costs and improve patient access.

1 investor

Viridaxis produces parasitoids for organic and integrated crop protection, serving agricultural customers seeking sustainable pest management solutions. The company invests in research and development to improve agricultural sustainability.

1 investor

Virilitas Labs develops research-led technologies focused on male fertility and reproductive health, drawing on over 20 years of study in reproduction and genetics. It aims to translate scientific research into products supporting couples with male infertility challenges.

1 investor

Viriom Inc. develops a pipeline of treatments for infectious diseases (blood-borne and respiratory viral diseases) and malignant diseases (solid tumors) through a global drug development platform built with partner networks. The company aims to broaden access to new therapies in both developed and developing countries.

1 investor

Virogin develops oncolytic virus therapies and mRNA vaccines for cancer treatment, combining immunotherapy approaches to create immuno-oncology therapeutics for patients with serious cancers.

1 investor

Vironexis is a clinical-stage biotechnology company developing an in vivo protein engineering platform called TransJoin, which uses non-integrating AAV vectors to instruct a patient's liver to continuously secrete bispecific T-cell engagers from a single IV dose. Its pipeline targets hematologic malignancies, solid tumors, and immune disorders, with lead candidates VNX-101 (CD19+ leukemias and lymphomas) and VNX-202 (HER2+ cancers) in Phase 1/2 clinical trials.

1 investor

Mid-stage drug developer of botanical anti-viral topical prescription candidates for skin diseases; acquired by TFS Corporation in 2017.

1 investor

Virtuoso Therapeutics is an oncology-focused biotech developing novel bispecific antibody therapies aimed at addressing challenges like efficacy and therapeutic window. It operates a hybrid US-China model for virtual R&D, drawing on science and talent from both regions.

1 investor

Visano Theranostics develops PSMA-targeted nanobubble contrast agents that add real-time molecular imaging to standard ultrasound workflows for the diagnosis and treatment of prostate cancer. The company licensed nanobubble technologies from Case Western Reserve University and is focused on precision oncology for prostate cancer.

1 investor

Viscient Biosciences develops drugs by studying human 3D tissue models combined with multi-omics analysis to understand disease mechanisms. The company initially focuses on non-alcoholic steatohepatitis (NASH) drug discovery.

1 investor

1 investor

VistaraBio provides research tools and services for drug discovery, including modified protein assays, post-translationally modified protein catalogs, and cell screening platforms using bioactive peptides. The company serves pharmaceutical and biotech researchers developing small molecule and protein degrader therapeutics.

1 investor

BetteRx (formerly Vitae Industries) builds the AutoCompounder, an automated dosage-making system with a vetted compound formulary that helps 503A compounding pharmacists produce personalized medications more consistently and in line with FDA regulations. It serves compounding pharmacies in the US, with installations across the country.

1 investor

The BARDA Accelerator Network fosters health security innovation ecosystems worldwide and accelerates development and commercialization of next-generation health security solutions. It is established by the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services.

1 investor

Vitalief is a research operations partner that embeds experienced staff inside clinical research programs to run work across study start-up, financial and revenue cycle operations, workforce capacity, and portfolio delivery. It serves clinical research organizations and sponsors across the United States.

1 investor

A pharmaceutical company that develops and manufactures injectable medications across therapeutic areas including infectious disease, cardiology, anesthesia, gastroenterology, neurology, and oncology, as well as ophthalmic solutions and semi-solid products.

1 investor

Vitaliti is developing a therapeutic exercise mimetic intended to restore the ability to gain the benefits of exercise for people with cardiopulmonary disease. The company targets patients with debilitating cardiopulmonary conditions.

1 investor

Vitroprobe Analytics develops a patented biomolecular analysis method using Atom Probe Tomography to examine drug targets and their interactions at near-atomic resolution, helping pharmaceutical developers design and fine-tune new drugs. The company works in collaboration with academia and industry and originated from research at Chalmers University of Technology.

1 investor

Vitroscope develops products and solutions that combine scientific expertise with product development capabilities, supported by advisors from leading research institutions. The company focuses on immunology and cell models based on its advisory team's expertise.

1 investor

VITRUVIAE is a biotechnology company developing cancer immunotherapies that target sugars and lipids found on tumor cells but not on healthy cells, aiming to improve tumor selectivity and counter drug resistance. Its dual sugar-lipid targeting platform is engineered into formats such as T-cell engagers, CAR immune cells, and radioactive delivery platforms, with a lead program (VTRU200) for acute myeloid leukemia.

1 investor

Viva In Vitro Diagnostics is a biotech company that researches and develops diagnostic solutions and services focused on the NLRP3 inflammasome and inflammatory processes, including biomarkers for early prognosis and patient stratification in sepsis. A spin-off of Murcia's biomedical research institute (IMIB), it serves hospitals, laboratories, and research centers, with its own lab in the Parque Científico de Murcia, Spain.

1 investor

Vivacelle Bio develops phospholipid nanoparticle therapies (VBI-S and VBI-1) that restore intravascular volume and redirect excess nitric oxide to treat hypovolemia in patients with septic shock or severe blood loss. The company is running a Phase III trial for its lead asset VBI-S in septic shock patients across U.S. sites.

1 investor

Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases. The company operates research operations in Colorado and Austria.

1 investor

Vivalyx develops organ revitalization technology aimed at improving organ vitality for transplantation. The company works in the medical biotechnology field.

1 investor